364 related articles for article (PubMed ID: 12480560)
21. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.
Bucci L; Palmieri GC
Curr Med Res Opin; 1993; 13(2):109-18. PubMed ID: 8325041
[TBL] [Abstract][Full Text] [Related]
22. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study.
Sanyal A; Younossi ZM; Bass NM; Mullen KD; Poordad F; Brown RS; Vemuru RP; Mazen Jamal M; Huang S; Merchant K; Bortey E; Forbes WP
Aliment Pharmacol Ther; 2011 Oct; 34(8):853-61. PubMed ID: 21848797
[TBL] [Abstract][Full Text] [Related]
23. Rifaximin: new therapeutic indication and future directions.
Rivkin A; Gim S
Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
[TBL] [Abstract][Full Text] [Related]
24. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial.
Uribe M; Campollo O; Vargas F; Ravelli GP; Mundo F; Zapata L; Gil S; Garcia-Ramos G
Hepatology; 1987; 7(4):639-43. PubMed ID: 3301614
[TBL] [Abstract][Full Text] [Related]
25. Effects of long-term administration of low-dose lactitol in patients with cirrhosis but without overt encephalopathy.
Salerno F; Moser P; Maggi A; Vitaliani G; Benetti G
J Hepatol; 1994 Dec; 21(6):1092-6. PubMed ID: 7699233
[TBL] [Abstract][Full Text] [Related]
26. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Gluud LL; Vilstrup H; Morgan MY
Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
[TBL] [Abstract][Full Text] [Related]
27. Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy.
Heredia D; Terés J; Orteu N; Rodés J
J Hepatol; 1988 Aug; 7(1):106-10. PubMed ID: 3053887
[TBL] [Abstract][Full Text] [Related]
28. Rifaximin for the treatment of hepatic encephalopathy.
de Melo RT; Charneski L; Hilas O
Am J Health Syst Pharm; 2008 May; 65(9):818-22. PubMed ID: 18436728
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Rifaximin in prevention of recurrence of hepatic encephalopathy in patients with cirrhosis of liver.
Ali B; Zaidi YA; Alam A; Anjum HS
J Coll Physicians Surg Pak; 2014 Apr; 24(4):269-73. PubMed ID: 24709242
[TBL] [Abstract][Full Text] [Related]
30. [Rifaximin in the treatment of hepatic encephalopathy].
Lata J; Hůlek P; Fejfar T; Spicák J; Drastich P; Marecek Z; Brůha R; Husová L; Senkyrík M
Vnitr Lek; 2002 Jun; 48(6):578-82. PubMed ID: 12132365
[TBL] [Abstract][Full Text] [Related]
31. Rifaximin is an efficacious treatment for the Parkinsonian phenotype of hepatic encephalopathy.
Kok B; Foxton MR; Clough C; Shawcross DL
Hepatology; 2013 Oct; 58(4):1516-7. PubMed ID: 23471844
[No Abstract] [Full Text] [Related]
32. Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double-blind controlled trial.
Glal KAM; Abd-Elsalam SM; Mostafa TM
J Hepatobiliary Pancreat Sci; 2021 Oct; 28(10):812-824. PubMed ID: 33768619
[TBL] [Abstract][Full Text] [Related]
33. Rifaximin in the treatment of chronic hepatic encephalopathy.
Puxeddu A; Quartini M; Massimetti A; Ferrieri A
Curr Med Res Opin; 1995; 13(5):274-81. PubMed ID: 7555036
[TBL] [Abstract][Full Text] [Related]
34. [Role of rifaximin in the treatment of hepatic encephalopathy].
Sanchez-Delgado J; Miquel M
Gastroenterol Hepatol; 2016 Apr; 39(4):282-92. PubMed ID: 26545947
[TBL] [Abstract][Full Text] [Related]
35. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.
Paik YH; Lee KS; Han KH; Song KH; Kim MH; Moon BS; Ahn SH; Lee SJ; Park HJ; Lee DK; Chon CY; Lee SI; Moon YM
Yonsei Med J; 2005 Jun; 46(3):399-407. PubMed ID: 15988813
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of rifaximin in management of hepatic encephalopathy.
Wahib AA; El-Deen Salem MN; Ahmed MA; El-Dessouky YM; El-Tiby DM; El-Mola K; El-Sayed AM
J Egypt Soc Parasitol; 2014 Dec; 44(3):677-85. PubMed ID: 25643509
[TBL] [Abstract][Full Text] [Related]
37. Disaccharides in the treatment of hepatic encephalopathy.
Sharma P; Sharma BC
Metab Brain Dis; 2013 Jun; 28(2):313-20. PubMed ID: 23456517
[TBL] [Abstract][Full Text] [Related]
38. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis.
Cammà C; Fiorello F; Tinè F; Marchesini G; Fabbri A; Pagliaro L
Dig Dis Sci; 1993 May; 38(5):916-22. PubMed ID: 8482191
[TBL] [Abstract][Full Text] [Related]
39. Treatment options for hepatic encephalopathy.
Schiano TD
Pharmacotherapy; 2010 May; 30(5 Pt 2):16S-21S. PubMed ID: 20412036
[TBL] [Abstract][Full Text] [Related]
40. Durability of rifaximin response in hepatic encephalopathy.
Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
